Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Short term Debt (2018 - 2023)

Historic Short term Debt for Protagonist Therapeutics (PTGX) over the last 6 years, with Q2 2023 value amounting to $10000.0.

  • Protagonist Therapeutics' Short term Debt fell 8750.0% to $10000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $10000.0, marking a year-over-year decrease of 8750.0%. This contributed to the annual value of $69000.0 for FY2022, which is 9232.48% down from last year.
  • Protagonist Therapeutics' Short term Debt amounted to $10000.0 in Q2 2023, which was down 8750.0% from $22000.0 recorded in Q1 2023.
  • Over the past 5 years, Protagonist Therapeutics' Short term Debt peaked at $11.4 million during Q2 2021, and registered a low of $10000.0 during Q2 2023.
  • For the 5-year period, Protagonist Therapeutics' Short term Debt averaged around $1.8 million, with its median value being $1.0 million (2019).
  • In the last 5 years, Protagonist Therapeutics' Short term Debt skyrocketed by 103619.14% in 2021 and then tumbled by 9929.8% in 2022.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Short term Debt stood at $1.3 million in 2019, then surged by 116.48% to $2.7 million in 2020, then plummeted by 67.09% to $899000.0 in 2021, then plummeted by 92.32% to $69000.0 in 2022, then tumbled by 85.51% to $10000.0 in 2023.
  • Its Short term Debt stands at $10000.0 for Q2 2023, versus $22000.0 for Q1 2023 and $69000.0 for Q4 2022.